3B Blackbio DX Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #34 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
3B Blackbio DX Ltd Q1 FY27 key numbers
- Revenue
- Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. 60.5%.
As stated in 3B Blackbio DX Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on 3B Blackbio DX Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Q1 2026-27 Consolidated EBITDA: ₹1,466.54 Lakh, down from ₹1,619.43 Lakh in Q1 2025-26 (includes Coris' negative EBITDA of ₹(352.24) Lakh).
From 3B Blackbio DX Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. 60.5%.
- Export sales in Q1 2026-27: ₹596.28 Lakh vs ₹430.90 Lakh in Q1 2025-26 — 38% growth.
- 3B Standalone Q1 sales grew by 19%.
- MDx Division revenue (excluding Coris): ₹2,342.90 Lakh vs ₹1,996.06 Lakh — about 17.4% growth.
- Coris Q1 2026-27 revenue: €796K (~₹862.83 Lakh), slight increase vs previous year.
- Sales model projection: Contractual/Reagent rental expected to contribute 20%-25% of total revenue long term.
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is currently operating at ~65% installed capacity, with potential to scale to 100% during seasonal spikes; lean season utilization is ~50%, allowing flexibility. (Page 45)
- Funds will be deployed partly in the joint venture in Manchester, UK, as needed. (Page 45)
- (Pages 29, 45)
- Existing & utilized capacity is implied to support growth without immediate expansion. (Page 45)
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Coris BioConcept SRL received a HAT order of EUR 1.41M to be supplied in Q3, December 2026 (Page 29).
- The company had a Belgium Government Order for HAT valued at EUR 6.0M received in February 2024 to be supplied over 4 years (Page 29).
- The Middle East market shows strong order inflow reflecting growing traction (Page 24).
2 more points from 3B Blackbio DX Ltd's call on order book
Create a free account to keep reading this call
3B Blackbio DX Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio's management said in earlier quarters
Others in Healthcare Services this season
- Aatmaj Health (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- Thyrocare Technologies (Q1 FY27)
Pathology business grew ~27%; franchisee business grew ~23-27% YoY, reflecting strong volume growth. Key concall takeaways from Thyrocare Technologies Ltd's Q1…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q1 FY27 results?
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Q1 2026-27 Consolidated EBITDA: ₹1,466.54 Lakh, down from ₹1,619.43 Lakh in Q1 2025-26 (includes Coris' negative EBITDA of ₹(352.24) Lakh).
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is currently operating at ~65% installed capacity, with potential to scale to 100% during seasonal spikes; lean season utilization is ~50%, allowing flexibility.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
